Physician profile
Manish Goyal
NPI 1710220389
$1,930.44
in general payments reported to CMS, 2019-2025
21 companies · $517 in 2025
The $517 reported for 2025 was more than what 90% of Hospitalist providers received nationally (typical 2025 total: $85.87).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $304 · 2020: $113 · 2022: $107 · 2023: $549 · 2024: $340 · 2025: $517.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,348 · Education: $58.09.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,347.54 |
| Education | $58.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $245.06 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $215.89 | 2019-2024 | Farxiga, Lokelma |
| Novartis Pharmaceuticals Corporation | $206.36 | 2023-2025 | |
| Ani Pharmaceuticals, INC. | $161.90 | 2022-2025 | Purified Cortrophin Gel |
| Calliditas Therapeutics US INC. | $159.72 | 2024-2025 | Tarpeyo |
| Akebia Therapeutics INC | $141.77 | 2019-2024 | Auryxia, Vafseo |
| Otsuka America Pharmaceutical, INC. | $113.82 | 2019-2025 | Jynarque |
| Mallinckrodt Hospital Products INC. | $88.26 | 2020-2025 | Terlivaz, Acthar |
| Ardelyx, INC. | $84.42 | 2023-2025 | Ibsrela |
| Vifor Pharma, INC. | $83.79 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $80.04 | 2023-2025 | Jardiance |
| Glaxosmithkline, LLC. | $79.51 | 2023-2024 | Benlysta, Jesduvroq |
| Aurinia Pharma U.S., INC. | $55.18 | 2023-2025 | Lupkynis |
| Amgen INC. | $54.39 | 2019-2025 | Tavneos, Parsabiv, Aranesp |
| Mallinckrodt Enterprises LLC | $45.41 | 2019 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Opko Pharmaceuticals, LLC | $30.72 | 2019 | |
| Horizon Therapeutics Plc | $29.14 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $15.35 | 2019 | |
| Lilly USA, LLC | $14.65 | 2024 | Jardiance |
| Daiichi Sankyo INC. | $13.36 | 2019 | |
| Mylan Specialty L.P. | $11.70 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Manish Goyal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.